Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE164897_VemTra

Dataset summary for GSE164897_VemTra

Datast information	Dataset	GSE164897_VemTra
	PMID	34591417
	Raw data ID/link	PRJNA692421
	Organism	Homo sapiens
	Source	A375 cell line
	Tissue	Cell line
	Cancer type level1	Melanoma
	Cancer type level2	B+E2:E57RAFV600E-mutant melanoma
	Regimen	vemurafenib + trametinib
	Drug type	Targeted therapy
	Sample size	resistant 1, sensitive 1
	Cell number	15718
	Extract protocol	10x genomics
	Data processing	CellRanger
	Public date	Public on Jan 16, 2021
	Description	This dataset has 1 cell line with a sensitive pre-treatment sample and a resistant post-treatment sample.

Top

Drug summary for GSE164897_VemTra

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Vemurafenib"	DB08881	small molecule	BRAF	P15056
"Trametinib"	DB08911	small molecule	MAP2K1; MAP2K2	Q02750; P36507

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types	Umap of conditions
Umap of cell clusters	Cell ratio of drug-resistant and sensitive groups within each cluster

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
DDX24	ENSG00000273761	0.285953	0.00e+00	0.00e+00	0.343	0.23	Malignant cells	NA
RAC1	ENSG00000136238	0.284231	0.00e+00	0.00e+00	0.434	0.357	Malignant cells	NA
ATP5MF	ENSG00000241468	0.283834	0.00e+00	0.00e+00	0.867	0.878	Malignant cells	NA
SDHC	ENSG00000143252	0.282366	8.41e-45	1.36e-40	0.532	0.502	Malignant cells	NA
LAPTM4A	ENSG00000068697	0.281619	0.00e+00	0.00e+00	0.34	0.255	Malignant cells	NA
LSM5	ENSG00000106355	0.280097	0.00e+00	0.00e+00	0.69	0.699	Malignant cells	NA
IRF2BP2	ENSG00000168264	0.279635	0.00e+00	0.00e+00	0.263	0.125	Malignant cells	NA
MBNL1	ENSG00000152601	0.276389	0.00e+00	0.00e+00	0.26	0.126	Malignant cells	NA
TCEAL4	ENSG00000133142	0.274434	0.00e+00	9.08e-43	0.415	0.348	Malignant cells	NA
ZFAND5	ENSG00000107372	0.272496	0.00e+00	0.00e+00	0.258	0.127	Malignant cells	NA
SEC11A	ENSG00000140612	0.272446	0.00e+00	0.00e+00	0.73	0.755	Malignant cells	NA
TMEM126A	ENSG00000171202	0.271767	0.00e+00	0.00e+00	0.366	0.281	Malignant cells	NA
NDUFB9	ENSG00000147684	0.269829	0.00e+00	0.00e+00	0.828	0.843	Malignant cells	NA
SDCBP	ENSG00000137575	0.269725	0.00e+00	0.00e+00	0.271	0.138	Malignant cells	NA
PPIC	ENSG00000168938	0.268811	0.00e+00	0.00e+00	0.27	0.148	Malignant cells	NA
EIF3A	ENSG00000107581	0.262816	3.34e-40	5.33e-36	0.487	0.448	Malignant cells	NA
COX7B	ENSG00000131174	0.262504	0.00e+00	0.00e+00	0.846	0.846	Malignant cells	NA
UBE2L3	ENSG00000185651	0.262083	2.12e-35	3.39e-31	0.465	0.434	Malignant cells	NA
KHDRBS1	ENSG00000121774	0.262081	0.00e+00	0.00e+00	0.338	0.238	Malignant cells	NA
ATP5MC3	ENSG00000154518	0.260743	3.57e-43	5.71e-39	0.672	0.695	Malignant cells	NA
TXN	ENSG00000136810	0.259415	0.00e+00	1.12e-44	0.987	0.986	Malignant cells	NA
ARF4	ENSG00000168374	0.256697	2.63e-24	4.20e-20	0.365	0.327	Malignant cells	NA
SOD1	ENSG00000142168	0.256679	2.14e-30	3.42e-26	0.639	0.681	Malignant cells	NA
KMT2A	ENSG00000118058	0.255602	0.00e+00	0.00e+00	0.259	0.136	Malignant cells	NA
CDC26	ENSG00000176386	0.255464	0.00e+00	0.00e+00	0.331	0.233	Malignant cells	NA
PGK1	ENSG00000102144	0.253956	2.42e-37	3.86e-33	0.609	0.612	Malignant cells	NA
DDX3X	ENSG00000215301	0.250901	0.00e+00	0.00e+00	0.292	0.186	Malignant cells	NA
MAGEA3	ENSG00000221867	0.250332	0.00e+00	0.00e+00	0.337	0.251	Malignant cells	NA
SLC7A5	ENSG00000103257	-0.250095	0.00e+00	0.00e+00	0.187	0.403	Malignant cells	NA
UPF3A	ENSG00000169062	-0.250359	0.00e+00	0.00e+00	0.134	0.35	Malignant cells	NA
CENPF	ENSG00000117724	-0.250737	0.00e+00	0.00e+00	0.075	0.251	Malignant cells	NA
AMIGO2	ENSG00000139211	-0.251019	0.00e+00	0.00e+00	0.085	0.262	Malignant cells	NA
RANGRF	ENSG00000108961	-0.251114	0.00e+00	0.00e+00	0.07	0.269	Malignant cells	NA
CD47	ENSG00000196776	-0.251253	0.00e+00	0.00e+00	0.069	0.268	Malignant cells	NA
SRPK2	ENSG00000135250	-0.251457	0.00e+00	0.00e+00	0.113	0.331	Malignant cells	NA
RRBP1	ENSG00000125844	-0.251963	0.00e+00	0.00e+00	0.069	0.269	Malignant cells	NA
LARP7	ENSG00000174720	-0.252141	0.00e+00	0.00e+00	0.09	0.296	Malignant cells	NA
AP1M1	ENSG00000072958	-0.252991	0.00e+00	0.00e+00	0.058	0.257	Malignant cells	NA
SLC20A1	ENSG00000144136	-0.253512	0.00e+00	0.00e+00	0.087	0.289	Malignant cells	NA
ARL16	ENSG00000214087	-0.254103	0.00e+00	0.00e+00	0.062	0.264	Malignant cells	NA
DDIT3	ENSG00000175197	-0.254434	0.00e+00	0.00e+00	0.118	0.371	Malignant cells	NA
CUEDC2	ENSG00000107874	-0.254624	0.00e+00	0.00e+00	0.137	0.36	Malignant cells	NA
TRPT1	ENSG00000149743	-0.255039	0.00e+00	0.00e+00	0.08	0.287	Malignant cells	NA
BLOC1S2	ENSG00000196072	-0.255389	0.00e+00	0.00e+00	0.061	0.265	Malignant cells	NA
SLC39A1	ENSG00000143570	-0.255509	0.00e+00	0.00e+00	0.204	0.433	Malignant cells	NA
MTCH1	ENSG00000137409	-0.255585	0.00e+00	0.00e+00	0.172	0.401	Malignant cells	NA
ISCA1	ENSG00000135070	-0.256613	0.00e+00	0.00e+00	0.094	0.306	Malignant cells	NA
TIMM8B	ENSG00000150779	-0.25668	0.00e+00	0.00e+00	0.33	0.585	Malignant cells	NA
RWDD1	ENSG00000111832	-0.256938	0.00e+00	0.00e+00	0.256	0.502	Malignant cells	NA
SERPINE2	ENSG00000135919	-0.257302	0.00e+00	0.00e+00	0.891	0.934	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	3.90e-06	2.00e-05	1480	781	82	23467	Malignant cells	BAX,CDK4,CTNNB1,DNMT1,DUSP6,GSTP1,HMGA1,HMGA2,HMGB1,PKM,MAP1LC3B,NFKB1,PARP1,RHOA,S100A4,SHC1,ST3GAL4,SOX4,STMN1,SLC25A5,AKAP12,ALDH1A3,ATG3,BAD,BID,BRD4,CCND1,CD44,HSPD1,CLTC,CAPNS1,DDIT3,EIF3A,HSP90B1,ERCC1,FTL,FUS,GAPDH,NR3C1,HSPA8,HSPB1,EIF4A1,IL24,KDM5B,LDHA,MTDH,MAGEA3,NQO1,PGK1,AGPAT2,POMP,PRKDC,PSMB5,PSMG2,RAC1,RAP1B,ERBB3,RRM2,HNRNPA1,SDHB,SMC4,SRI,SOX10,SRSF2,STAT3,TGFA,TGFB2,TMED3,TMEM54,TOP1,UBE2C,YBX1,ENO1,MAGEA4,GNAS,CALR,NPM1,EIF4EBP1,PPP3CA,PMVK,TRIB3,BIRC2
Drug Inactivation by Structure Modification	2.40e-01	6.00e-01	1480	27	3	23467	Malignant cells	GSTP1,GSS,NME1
Irregularity in Drug Uptake and Drug Efflux	6.90e-01	1.00e+00	1480	37	2	23467	Malignant cells	SLC3A2,SLC7A5
Aberration of the Drug's Therapeutic Target	8.30e-01	1.00e+00	1480	90	4	23467	Malignant cells	CDK4,NPM1,COMT,TOP2A
Epigenetic Alteration of DNA, RNA or Protein	1.00e+00	1.00e+00	1480	455	13	23467	Malignant cells	DNMT1,EIF4G2,LMNA,TRIP6,PMAIP1,GAPDH,SMC4,TIMP1,MALAT1,GDI2,PPP1R15A,MT-CO2,NORAD

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	hdpi__TP73	5.09	0.0783	TP73 (directAnnotation).	Malignant cells
	metacluster_141.4	4.77	0.0751	GLIS2 (directAnnotation).	Malignant cells
	swissregulon__hs__ETV6	4.22	0.0695	ETV6 (directAnnotation).	Malignant cells
	hocomoco__TYY2_HUMAN.H11MO.0.D	4.11	0.0683	YY2 (directAnnotation).	Malignant cells
	transfac_pro__M06135	4.07	0.068	ZNF28 (directAnnotation).	Malignant cells
	metacluster_141.6	4.01	0.0673	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).	Malignant cells
	flyfactorsurvey__pho_SOLEXA_F1-3	3.81	0.0653	YY1 (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	3.54	0.0626	ETV5; HOXA2 (directAnnotation).	Malignant cells
	metacluster_155.3	3.47	0.0619	PLAG1 (directAnnotation). PLAG1 (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	3.27	0.0598	ELK1; TEF (directAnnotation).	Malignant cells

Page: 1 2 3

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	8.66	0.0737	ETS2 (directAnnotation).	Malignant cells
	transfac_pro__M04826	7.51	0.0667	EP300 (directAnnotation).	Malignant cells
	jaspar__MA1483.2	6.57	0.061	ELF2 (directAnnotation).	Malignant cells
	hdpi__FLI1	6.32	0.0595	FLI1 (directAnnotation).	Malignant cells
	metacluster_191.3	6.25	0.0591	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_191.2	6.15	0.0584	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_166.2	5.86	0.0567	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	5.76	0.0561	ELF2 (directAnnotation).	Malignant cells
	metacluster_166.4	5.73	0.0559	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	jaspar__MA1933.1	5.61	0.0551	SREBF2 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
ETV4	metacluster_191.3	down	Malignant cells	NA
ETV4	metacluster_166.2	down	Malignant cells	NA
ETV4	metacluster_166.4	down	Malignant cells	NA
ETV4	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	down	Malignant cells	NA
ETV4	hdpi__ETV4	down	Malignant cells	NA
ETV4	taipale_tf_pairs__FOXO1_ETV4_RCCGGAWGTKKN_CAP	down	Malignant cells	NA
ETV4	metacluster_138.2	down	Malignant cells	NA
ETV4	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	down	Malignant cells	NA
ETV4	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	down	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."